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BACKGROUND AND PURPOSE
Efavirenz (EFV) is widely used in the treatment of HIV-1 infection. Though highly efficient, there is growing concern about
EFV-related side effects, the molecular basis of which remains elusive.
EXPERIMENTAL APPROACH
In vitro studies were performed to address the effect of clinically relevant concentrations of EFV (10, 25 and 50 mM) on human
hepatic cells.
KEY RESULTS
Cellular proliferation and viability were reduced in a concentration-dependent manner. Analyses of the cell cycle and several
cell death parameters (chromatin condensation, phosphatidylserine exteriorization, mitochondrial proapoptotic protein
translocation and caspase activation) revealed that EFV triggered apoptosis via the intrinsic pathway. In addition, EFV directly
affected mitochondrial function in a reversible manner, inducing a decrease in mitochondrial membrane potential and an
increase in mitochondrial superoxide production, followed by a reduction in cellular glutathione content. The rapidity of these
actions rules out any involvement of mitochondrial DNA replication, which, until now, was thought to be the main
mechanism of mitochondrial toxicity of antiretroviral drugs. Importantly, we also observed an increase in mitochondrial mass,
manifested as an elevated cardiolipin content and enhanced expression of mitochondrial proteins, which was not paralleled
by an increase in the mtDNA/nuclear DNA copy number ratio. The toxic effect of EFV was partially reversed by antioxidant
pretreatment, which suggests ROS generation is involved in this effect.
CONCLUSION AND IMPLICATIONS
Clinically relevant concentrations of EFV were shown to be mitotoxic in human hepatic cells in vitro, which may be pertinent
to the understanding of the hepatotoxicity associated with this drug.
Abbreviations
AIF, apoptosis-inducing factor; cyt c, cytochrome c; DAPI, 4′,6-diamino-2-phenylindole; DMEM, Dulbecco’s modified
Eagle’s medium; EFV, Efavirenz; FBS, fetal bovine serum; FCCP, carbonylcyanide-4-(trifluoromethoxy)-phenylhydrazone;
FeTCPP, iron(III)-tetrakis (p-carboxyphenyl) porphyrin; FITC, fluorescein isothiocyanate; HAART, highly active
antiretroviral therapy; HUVEC, human umbilical vein endothelial cells; MEM, minimal essential medium; mtDNA,
mitochondrial DNA; NAO, 10-N-nonyl-acridine orange chloride; NNRTI, non-nucleoside-reverse-transcriptase inhibitor;
NRTI, nucleoside-reverse-transcriptase inhibitor; Dym, mitochondrial transmembrane potential; PI, propidium iodide;
ROS, reactive oxygen species; STS, staurosporine; TMRM, tetramethylrhodaminemethylester; TNF-a, tumour necrosis
factor-a; Trolox, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; WB, Western blotting
BJP British Journal ofPharmacology
DOI:10.1111/j.1476-5381.2010.00866.x
www.brjpharmacol.org
British Journal of Pharmacology (2010) 160 2069–2084 2069© 2010 The Authors
Journal compilation © 2010 The British Pharmacological Society
Introduction
Chronic administration of the various drugs
included under the term highly active antiretroviral
therapy (HAART) has changed the prognosis of
AIDS. Current practice guidelines recommend
the combined use of non-nucleoside-reverse-
transcriptase inhibitor (NNRTI) or boosted protease
inhibitor regimens with two nucleoside-reverse-
transcriptase inhibitors (NRTI) (Hammer et al.,
2008; AIDSInfo, 2010). Due to the special character-
istics of the disease, the development of these drugs
was particularly rapid and focused essentially on
clinical efficacy, that is, reduction in mortality.
However, as the disease has become a controlled
condition, there has been increasing emphasis
placed on the long-term adverse effects induced by
this life-long pharmacological treatment. The mito-
chondrion is a major target of drug-induced cyto-
toxicity, which occurs through a wide variety of
mechanisms such as inhibition or uncoupling of
oxidative phosphorylation, oxidative stress and/or
opening of the mitochondrial permeability transi-
tion pore (Labbe et al., 2008). Many important
adverse effects associated with HAART are known to
be the consequence of mitochondrial toxicity, but
they have been mainly attributed to the inhibition
by NRTI of mitochondrial DNA polymerase-g (Pol-g),
the enzyme responsible for mtDNA replication
(Martin et al., 1994; Walker et al., 2002). The effects
on mitochondria of NNRTIs, which do not inhibit
Pol-g, are less well documented, though some ele-
ments of the toxicity attributed to these drugs
resemble disorders induced by mitochondrial dys-
function (Sato, 2007; Abdul-Ghani and DeFronzo,
2008).
Efavirenz (EFV) is the most widely used NNRTI,
and although considered a safe drug, there is
growing concern that EFV-containing therapies are
associated with lipid and metabolic disorders, psy-
chiatric symptoms and hepatotoxicity (Tashima
et al., 2003; Gutierrez et al., 2005; Manfredi et al.,
2005). The clinical manifestations of these events
have been characterized, but the cellular and
molecular mechanisms underlying these detrimen-
tal effects of EFV remain largely unknown.
Up to 10% of HIV patients treated with EFV
exhibit increases in liver enzymes that may require
the treatment to be discontinued (Kappelhoff et al.,
2005). In the present study, we show that clinically
relevant concentrations of EFV induce a rapid mito-
toxic effect in human hepatic cells by a mechanism
independent of mitochondrial DNA replication.
EFV reduced cellular proliferation and viability in a
concentration-dependent manner, triggered apop-
tosis via the intrinsic pathway and modified several
parameters of mitochondrial function, including
the induction of oxidative stress and a significant
increase in mitochondrial mass. The fact that some
of these harmful effects were partially reversed by an
antioxidant treatment suggests that ROS generation
is implicated in their manifestation.
Methods
Reagents
Unless otherwise stated, chemical reagents were
purchased from Sigma-Aldrich (Steinheim,
Germany). EFV (Sustiva® 600 mg, Bristol-Myers
Squibb, Princeton, NJ, USA) was obtained from its
clinically available preparation and, once insoluble
substances were removed by filtration, was dissolved
in methanol (3 mg·mL-1). The purity (98–100%) and
stability of the solutions were evaluated by high-
performance liquid chromatography (HPLC) and
compared with a control solution of EFV purchased
from Sequoia Research Products (Pangbourne, UK).
No differences were detected in the stability and the
activity between this control solution and EFV
obtained from the galenic form. A concentration of
0.5% methanol was employed in all EFV treatments
and vehicle control experiments, versus which the
statistical analysis was always performed. This con-
centration of methanol did not have a significant
impact on any of the parameters studied.
Cell culture
Experiments were performed with the human hepa-
toblastoma cell line Hep3B (ATCC HB-8064). In spe-
cific cases, primary human hepatocytes obtained
from biopsies of patients (three women, three men)
undergoing surgical resection of liver tumours (Hos-
pital ‘La Fe’, Valencia, Spain) were employed.
Several experiments were also reproduced in
HUVEC obtained from fresh human umbilical cords
(Department of Gynaecology, Hospital Clínico Uni-
versitario, Valencia, Spain) and the human cervical
carcinoma cell line HeLa (ATCC CCL-2). Unless
stated otherwise, all reagents employed in cell
culture were purchased from Gibco (Invitrogen,
Eugene, OR, USA). Hep3B cells were cultured in
MEM supplemented with 1 mM non-essential
amino acids. HeLa cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) with a high
glucose concentration (4.5 mg·mL-1). Both Hep3B
and HeLa culture media were supplemented with
10% heat-inactivated fetal bovine serum (FBS),
penicillin (50 U·mL-1) and streptomycin
(50 mg·mL-1). HUVEC were isolated by extraction
with collagenase (Jaffe et al., 1973) and cultured in
EMG-2 medium supplemented with BulletKit com-
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ponents (Clonetics, Lonza, Walkersville, MD, USA)
according to the manufacturer’s instructions, and
with 50 U·mL-1 penicillin, 50 mg·mL-1 streptomycin
and 2.5 mg·mL-1 fungizone-Amphotericin B. Hepa-
tocytes were isolated from biopsies following a two-
step collagenase protocol (Pichard et al., 2006). In
brief, biopsies were first perfused (15 min) with dis-
sociation solution containing 0.05% collagenase,
20 mM HEPES, 120 mM NaCl, 5 mM KCl, 0.7 mM
CaCl2, 0.5% glucose, 100 mM sorbitol, 100 mM
manitol, 100 mM glutathione (GSH), 100 U·mL-1
penicillin, 100 mg·mL-1 streptomycin and
0.25 mg·mL-1 amphotericin B, pH 7.2. Further
homogenization was achieved with the addition of
0.2% collagenase (37°C, 20 min). The resulting cell
suspension was then filtered through a nylon mesh
(250 mm) and washed three times at 50¥ g (5 min)
in a culture medium containing advanced D-MEM/
F12 and William’s E medium (1:1) supplemented
with 0.29 g·L-1 glutamine, 0.04 mg·L-1 dexametha-
sone and 200 mg·L-1 glucagon. Cell viability (>80%)
was determined by trypan blue exclusion. Hepato-
cytes were seeded in type I collagen-coated dishes
(BD labware, Oxford, UK) and maintained for 72 h
in a culture medium containing 5% FBS, that was
refreshed every 24 h. A stable cell culture was
obtained in which at least 90% of cells were
hepatocytes.
All cell cultures were maintained in an incubator
(IGO 150, Jouan, Saint-Herblain Cedes, France) at
37°C in a humidified atmosphere of 5% CO2/95%
air (AirLiquide Medicinal, Valencia, Spain). Treat-
ments were always performed in complete cell
culture medium. The protocols employed complied
with European Community guidelines for the use of
human experimental models and were approved by
the Ethics Committee of the University of Valencia.
Proliferation and viability
Cells were seeded in 6-well plates, allowed to prolif-
erate exponentially for 3 days in the presence of EFV
and counted at 24, 48 and 72 h using a haemacy-
tometer (Bright Line Counting Improved Neubauer
Chamber, Hausser Scientific, Horsham, PA, USA).
In addition, we performed the MTT [3-(4,
5-dimethylthiazol-2-yl)-2,5-diprenyl tetrazolium
bromide] assay, which is a colorimetric assay based
on the ability of cells to reduce a soluble yellow
tetrazolium salt to blue formazan crystals
(Mosmann, 1983). This reduction takes place only
when mitochondrial reductase enzymes are active,
and is thus a marker of cell viability related to mito-
chondrial function. EFV treatment was performed
over a 24 h-period, in 96-well plates. MTT reagent
(Roche Diagnostics, Mannheim, Germany) was
added (20 mL per well) for the last 4 h of the treat-
ment. Cells were dissolved in DMSO (100 mL per
well, 5 min, 37°C) and absorbance was measured
using a ‘Multiscan’ plate-reader spectrophotometer
(Thermo Labsystems, Thermo Scientific, Rockford,
IL, USA).
Protein extracts and Western blotting
Protein extracts were obtained using t-75 flask cell
cultures of Hep3B cells. To obtain mitochondria-
enriched protein fraction, cells were lysed with
0.5 mL fractionation buffer (10 mM Tris-HCL pH
7.5, 0.25 M sucrose and 1 mM EDTA) on ice by
passage through a 23-gauge needle. Unbroken cells
were pelleted by 10 min centrifugation at 500¥ g at
4°C. The lysate was centrifuged again at 16100¥ g
for 30 min at 4°C. The pellet representing the mito-
chondrial fraction was suspended in 50 mL mito-
chondrial buffer (10 mM Tris-acetate pH 8.0, 0.5%
NP-40, 5 mM CaCl2, 1 mM DTT and ‘Complete
Mini’ protease inhibitor cocktail from Roche Diag-
nostics). Whole-cell protein extracts were obtained
by lysing cell pellets in 50–100 mL complete lysis
buffer (20 mM HEPES pH 7.4, 400 mM NaCl, 20%
(v/v) glycerol, 0.1 mM EDTA, 10 mM Na2MoO4,
1 mM DTT) supplemented with protease inhibitors
(‘Complete Mini’ protease inhibitor cocktail, and
‘Pefabloc’, both from Roche Diagnostics), and
phosphatase inhibitors mixture: 10 mM NaF, 10 mM
NaVO3, 10 mM p-nitrophenylphosphate (PNPP)
and 10 mM b-glycerolphosphate. Samples were vor-
texed, incubated on ice for 15 min, vortexed again
and centrifuged in a microcentrifuge at 16100¥ g
for 15 min at 4°C. Protein content was quantified
employing the ‘BCA Protein Assay Kit’ (Pierce,
Thermo Scientific). SDS-PAGE and WB were per-
formed using standard methods (Bio-Rad, Hercules,
CA, USA), with 40–50 mg of the protein extract, and
employing primary antibodies: anti-AIF (yProSci,
Poway, CA, USA) at 1:500 dilution, anti-actin at
1:500 (Sigma-Aldrich), anti-cyt c at 1:1000 (Zymed,
Invitrogen, Carlsbad, CA, USA), anti-Complex I
subunits 17, 20 and 39 kDa, anti-Complex IV
subunit II, anti-Complex V subunits a and b and
anti-Porin, all at 1:1000 and from Molecular Probes
(Invitrogen) and secondary antibodies: peroxidase-
labelled anti-rabbit IgG from Vector laboratories
(Burlingame, CA, USA) at 1:5000 and anti-mouse
antibody from Dako (Glostrup, Denmark) at
1:2000. Immunolabelling was detected using the
enhanced chemiluminescent reagent ECL (Amer-
sham, GE Healthcare, Little Chalfont, UK) or
SuperSignal WestFemto (Pierce, Thermo Scientific),
and was visualized with a digital luminescent
image analyser (FUJIFILM LAS 3000, Fujifilm).
ImageQuant software version 4.0. was used for
densitometric analysis.
BJPMitotoxic effect of Efavirenz in human hepatic cells
British Journal of Pharmacology (2010) 160 2069–2084 2071
Fluorescence microscopy and static cytometry
All treatments were performed in duplicate in
24-well plates, and 16–30 images per well were
recorded with a fluorescence microscope (IX81,
Olympus, Hamburg, Germany) coupled with a static
cytometry software ‘ScanR’ version 2.03.2
(Olympus).
Apoptosis
Bivariate Annexin V/PI analysis. Following 24 h
treatment with EFV, the medium was replaced with
HBSS containing 1 mM of the chromatin-specific dye
Hoechst 33342 and 0.5 mL AnnexinV-Fluorescein in
order to detect phosphatidylserine exteriorization,
and was incubated in the dark for 15 min at 37°C.
Thereafter, 0.5 mL of the chromatin-detecting dye
propidium iodide (PI) was added (5 min) to label
dead or damaged cells. Annexin V and PI solutions
were purchased in the form of Annexin-V-FLUOS
Staining kit (Roche Diagnostics). Staurosporine
(STS), a widely used protein kinase inhibitor, was
employed as a positive pro-apoptotic control
(Lakhani et al., 2006).
Detection of caspase-3, -9 and caspase-8. Activated
caspases can be detected in living cells with specific
cell-permeable, non-toxic fluorescent dyes. We used
CaspGLOWTM – Red Active Caspase-9, – Fluorescein
Active Caspase-3 and – Red Active Caspase-8 Stain-
ing kits (Biovision Research Products, Mountain
View, CA, USA). The assay employs RED-LEHD-FMK
(caspase-9), fluorescein isothiocyanate (FITC)-
DEVD-FMK (caspase-3) and RED-IETD-FMK
(caspase-8) as fluorescent markers. Cells were treated
with EFV for 24 h using 1 mM STS as a positive
control. The fluorochromes for caspase detection
and 1 mM Hoechst 33342 were subsequently added
and incubated in the dark for 30 min (37°C).
Mitochondrial membrane potential and
superoxide detection
Cells were treated with EFV or the vehicle for a
period of 1, 6 and 24 h. Fluorochromes 1 mM
Hoechst 33342 and 5 mM TMRM (to detect mem-
brane potential) or 5 mM MitoSOX (to detect mito-
chondrial superoxide), both from Molecular Probes
(Invitrogen), were added for the last 30 min of treat-
ment. FCCP (uncoupler of oxidative phosphoryla-
tion) or Rotenone (Complex I inhibitor) was used as
a positive control (Labbe et al., 2008). To assess the
reversibility of the effects, cells were treated for 1 h
with EFV, which was subsequently removed. Then,
30 min later, the fluorochromes were added for a
further 30 min incubation. The fluorescence detec-
tion filter set for both TMRM and MitoSOX was
excitation max 540/10 nm, dichroic filter 570 nm
and emission 590 nm LP.
The MitoSOX signal was also detected using a
‘Fluoroscan’ multi-well plate reader (Thermo Lab-
systems, Thermo Scientific), excitation/emission
maxima of 390/530 nm. Hep3B cells were incubated
with EFV for 24 h in 96-well plates and 5 mM
MitoSOX was added for the last 30 min. Cells were
then washed with HBSS and fluorescence was imme-
diately recorded. Fluoresence was also evaluated
prior to addition of MitoSOX, as autofluorescence
can be intense at near-UV wavelength.
Determination of mitochondrial mass
The fluorescent dye 10-N-nonyl-acridine orange
chloride (NAO) (Sigma-Aldrich), which specifically
binds to cardiolipin independently of the mito-
chondrial membrane potential, was used to monitor
mitochondrial mass (Wu et al., 2007). Cells were
treated with EFV or vehicle for 1, 6 or 24 h. Fluoro-
chromes (1 mM Hoechst 33342 and 0.5 mM NAO)
were added for the last 30 min of the treatment and
incubated in the dark. These experiments were also
performed using the fluorescent mitochondrial
stain Mitotracker Green FM 5 mM (Molecular Probes,
Invitrogen).
In order to study the involvement of ROS in the
effect of EFV, several static cytometry experiments
were performed where the cells were treated with
Trolox, a water-soluble analogue of vitamin E
(Forrest et al., 1994). In these experiments, cells were
cultured in the presence of Trolox for 1 h and then
EFV was added for a further 24 h incubation,
without the medium being refreshed.
Detection of GSH
GSH was detected by a fluorometric method using
monochlorobimane (Molecular Probes, Invitrogen),
which crosses the plasma membrane and forms an
intracellular fluorescent adduct in a reaction cataly-
sed by GSH S-transferase (Sebastiá et al., 2003). Fol-
lowing 4 h treatment with EFV in 96-well plates, the
culture medium was discarded and 100 mL HBSS
containing 0.04 mM monochlorobimane were
added to each well, which was followed by a 30 min
incubation in the dark, at 37°C. Fluorescence was
detected using a Fluoroscan (Thermo Labsystems,
Thermo Scientific) at lexc of 355 nm and lemis of
460 nm.
Determination of mtDNA copy number
Total cellular DNA was isolated using the QIAamp®
DNA Mini kit (Qiagen, Hilden, Germany) according
to the manufacturer’s instructions and quantified
using the NanoDrop® ND-1000 spectrophotometer
(NanoDrop Technologies, Wilmington, DE, USA).
DNA purity was verified by standard electrophoresis
using agarose gels. For the amplification of mtDNA
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content, we used the following primers, which are
complementary to sequences of the NDR1 gene:
mtF3212 5′-CACCCAAGAACAGGGTTTGT-3′ (for-
ward) and mtR3319 5′-TGGCCATGGGTATGTTG
TTTA-3′ (reverse). mtDNA content was quantified
relative to nuclear DNA (nDNA), for the amplifica-
tion of which we used primers complementary to
sequences of the nuclear gene cyclophylin A: CypAF
5′CGTCTCCTTTGAGCTGTTTG-3′ (forward) and
CypAR 5’TCTGGTCGTTCTTCTAGTGG-3′ (reverse).
PCR reactions were performed in a Carousel-based
LightCycler® 2.0 Real Time PCR System (Roche
Applied Biosystems). Both PCR reactions of mtDNA
and nDNA were performed using 25 ng total DNA,
mixed with LightCycler® FastStart DNA MasterPLUS
SYBR Green I master mix (Roche Applied Science)
following instructions in the manual. Forward and
reverse primers (0.5 mM for NDR1 and 1 mM for
CYPA) were added in a final reaction volume of
10 mL. For mtDNA amplification, reactions were per-
formed as follows: 5 min denaturalization at 95°C,
followed by 40 cycles of 1 s at 95°C, 5 s at 65°C and
6 s at 72°C. For nuclear DNA amplification, reac-
tions were performed as follows: 10 min denatural-
ization at 95°C, followed by 35 cycles of 1 s at 95°C,
5 s at 58°C and 18 s at 72°C. Standard curve was
included in each run and the specificity of the
amplified products was verified by melting curve
analysis and agarose gel electrophoresis. Data were
calculated as number of DNA copies. The results
shown are a summary of 3 independent experi-
ments (in duplicate) and are expressed as a ratio of
mtDNA/nDNA copy.
Presentation of data and statistical analysis
Data were analysed using GraphPad Prism v.3. soft-
ware with one-way ANOVA, followed by Newman–
Keuls multiple comparison test or Student’s t-test.
All values are expressed as mean  SEM and the
results were considered to be statistically significant
when: * P < 0.05, ** P < 0.01 and *** P < 0.001. In
most cases data are represented as percent of
control, the negative control (untreated cells) being
considered to be 100%.
Results
EFV treatment reduced cellular proliferation
and viability
Figure 1A shows the effect of EFV on cell survival
and proliferation of Hep3B cells. During the 3 day
experimental period evaluated, no significant differ-
ences in growth rate were detected in cells treated
with 10 mM. However, EFV 25 mM inhibited cell
growth, as the number of cells counted was lower
than in the control at 24 h and remained signifi-
cantly lower throughout the 72 h period of culture.
EFV 50 mM appeared to be cytotoxic, as most cells
did not survive the treatment. The decrease in the
number of EFV 50 mM-treated cells was substantial
after 24 h and was highly significant following 48
and 72 h (94.61  1.2% and 97  1.12% reduction
respectively). Figure 1B shows representative
inverted light microscopy images of Hep3B cells
after 24 h treatment with EFV at the three concen-
trations evaluated. It is noteworthy that, in addition
to a diminished proliferation, cells exposed to EFV
50 mM displayed clear morphological modifications
indicative of cellular stress. The MTT assay, the
results of which are shown in Figure 1C, confirmed
the inhibitory effect of 24 h treatment with EFV
50 mM and suggested that it was related to a dimin-
ished mitochondrial function. In order to determine
whether this inhibitory effect of EFV was cell-
specific, we also studied cellular proliferation and
viability in two other cell types (HeLa and HUVEC)
and found the inhibition more severe, reaching sta-
tistical significance in both cell lines within the first
24 h of treatment with EFV 25 mM. The absorbance
recorded in the MTT assay for HeLa cells was 79.09
 7.79% in EFV 25 mM, and 21.56  5.31% in EFV
50 mM (n = 9; *P < 0.05 for EFV 25 mM and ***P <
0.001 for EFV 50 mM vs. control), and the corre-
sponding values for HUVEC were 39.04  11.28%
and 3.24  0.29% (n = 6; **P < 0.01 for EFV 25 mM
and ***P < 0.001 for EFV 50 mM vs. control).
EFV treatment induced apoptosis
Although a clear trend towards apoptotic changes
was observed with 10 and 25 mM EFV, only those
induced by 50 mM EFV reached statistical signifi-
cance after the 24 h incubation period. Figure 2A
shows the results of the bivariate Annexin V/PI
analysis of exponentially growing Hep3B cells,
which was performed by static cytometry. Four dif-
ferent cellular subpopulations were evaluated: vital
(double negative), apoptotic (Annexin V+/PI-), late
apoptotic/necrotic (Annexin V+/PI+) and damaged
cells (Annexin V-/PI+) cells. The cytogram shows a
representative experiment in which EFV 50 mM-
treated cells displayed apoptotic features: 9.3% of
cells were Annexin V+/PI- compared with only 0.5%
of the negative control counterparts and 29.2% of
STS 1 mM-treated cells (positive control). Figure 2B
shows representative fluorescence microscopy
images of Hoechst-stained nuclei. Hep3B cells
undergoing treatment with 50 mM EFV exhibited
typical apoptotic features, such as chromatin con-
densation and nuclear fragmentation. We also
quantified the mean intensity of Hoechst
fluorescence in each nucleus and observed a consis-
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tent increase, paralleled by a decrease in the nuclear
area of Hoechst fluorescence, both hallmarks of
chromatin condensation. Although a trend was
observed, the changes in the bivariate Annexin V/PI
analysis and the intensity of Hoechst fluorescence in
cells treated with lower concentrations of EFV (10
and 25 mM) were not statistically significant. Con-
versely, the mean area of Hoechst fluorescence in
cells treated with EFV 10 mM was 99.52  0.55%,
this value decreased to 97.71  1.39% and 94.57 
1.11%, in those treated with 25 mM and 50 mM EFV,
respectively, whereas the mean Hoechst fluores-
cence augmented gradually from 103.23  1.56% in
cells treated with EFV10 mM, to 105.97  1.5% and
123.82 3.33% with EFV 25 and 50 mM respectively
(all values compared with the control value of
100%). We also analysed the expression of cyt c and
AIF, two pro-apoptotic mitochondrial proteins
which translocate to the cytosol and the nucleus,
respectively, during apoptosis (Danial and Korsm-
eyer, 2004; Li and Yuan, 2008). Incubation with EFV
for 24 h produced a concentration-dependent
reduction in the expression of both proteins in
mitochondria-enriched cellular fractions, which
reached statistical significance only with EFV 50 mM
(Figure 2C). The presence of apoptotic cells was also
observed during cell cycle analysis. Figure 3A and B
shows a significant increase in the subG1 peak in
EFV 50 mM-treated cells with respect to control. No
significant changes were observed with the lower
concentrations of EFV employed. Of note, EFV
50 mM treatment also displayed a significantly lower
percentage of cells in the G1 peak and an increase in
the G2M subpopulation, pointing to a cell cycle
arrest in G2M. It should be pointed out that the
static cytometry experiments confirmed the cyto-
toxic effect of 50 mM EFV on cellular proliferation
and viability described in Figure 1 with other tech-
niques. For example, Hoechst fluorescence of 30
fields per well (Figure 2A) detected 8022 cells in the
untreated control, 3118 cells with the EFV 50 mM-
treatment and 1576 cells with the 1 mM STS-
treatment. Further confirmation of the pro-apototic
effect of EFV is provided by studying the activation
of caspases as one of the early hallmarks of several
apoptotic pathways (Danial and Korsmeyer, 2004;
Figure 1
Effect of Efavirenz (EFV) treatment on cellular proliferation and viability of Hep3B cells (A) Cell count over 3 days using a haemacytometer revealed
a concentration-dependent inhibition of cellular proliferation. **P < 0.01, ***P < 0.001 versus vehicle. (B) Representative inverted light microscopy
images (10x) of cell culture treated with EFV for 24 h. (C) MTT assay of exponentially growing cells after 24 h of culture in the presence of EFV.
Data (mean  SEM, n = 3–6) were analysed by a one-way ANOVA multiple comparison test followed by Newman–Keuls test, significance versus
vehicle *P < 0.05.
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Figure 2
Activation of apoptosis in Hep3B cells after 24 h treatment with Efavirenz (EFV). (A) Representative histograms (Bivariate Annexin V/PI analysis) of
untreated control cells, and cells treated with 50 mM EFV and 1 mM STS, showing the existence of 4 cellular populations: AnnV-/PI-, AnnV+/PI-,
AnnV-/PI+ and AnnV+/PI+ (% of each population for all three conditions is provided) (B) Nuclear morphology by Hoechst staining. Left panel:
representative fluorescence microscopy images (40x). Arrows show typically apoptotic nuclei. Right panel: summary of the Hoechst fluorescence
data, calculated as % of control (untreated cells) fluorescence, which was considered 100%. (C) Western blot analysis using mitochondria-enriched
cellular fractions. Representative WB image and histogram expressing quantification of protein expression. Quantification was performed by
densitometry and the results (mean  SEM, n = 4–9) are expressed as protein expression in relation to that of untreated cells in each individual
experiment, which was considered 100%. Statistical analysis was performed by one-way ANOVA multiple comparison test followed by Newman–
Keuls test (*P < 0.05, ***P < 0.001 vs. vehicle). The positive control was independently analysed by Student’s t-test (# P < 0.001).
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Lakhani et al., 2006; Li and Yuan, 2008). Figure 3C
shows how EFV 50 mM induced activation of
caspase-3 and -9, but not of caspase-8 (data not
shown), a finding which points to the triggering of
the intrinsic (mitochondrial) but not the extrinsic
pathway of apoptosis. A summary showing the cel-
lular population positive for caspase-3 and caspase-9
after 24 h EFV treatment is given in Figure 3D. These
experiments revealed that 19.44  8.50% of EFV
50 mM-treated cells were caspase-3 positive whereas
28.55  7.41% proved caspase-9 positive. Interest-
ingly, EFV 25 mM-treated cells only showed
caspase-9 activation.
EFV treatment compromised
mitochondrial function
To analyse the mitotoxic potential of EFV, we
assessed its effect on mitochondrial superoxide pro-
duction using the mitochondria-targeted fluoro-
chrome MitoSOX. In all three periods evaluated, 1, 6
and 24 h (Figure 4A), incubation of Hep3B cells with
EFV 50 mM led to a significant increase in mitochon-
drial superoxide production, detected as increase in
MitoSOX fluorescence. Importantly, the increase in
mitochondrial superoxide accumulated over time.
In particular, at 6 and 24 h treatment the values
obtained with EFV 50 mM were very similar to those
obtained with Rotenone, a well-known inducer of
superoxide production at Complex I of the mito-
chondrial electron chain. Unlike in most of the pre-
vious experiments with apoptosis, a clear and
statistically significant effect was also observed with
EFV 25 mM. EFV 10 mM induced no effects. Given
that in live cells the selectivity of ethidium-based
probes such as MitoSOX for superoxide is compli-
cated by auto-oxidation and superoxide-
Figure 3
Cell cycle analysis by static cytometry (Hoechst fluorescence) in Hep3B cells treated with vehicle or Efavirenz (EFV) 50 mM for 24 h. Representative
cytograms (A) and a summary histogram (B) are shown; statistical analysis was performed by one-way ANOVA multiple comparison test followed
by Newman–Keuls test (*P < 0.05 vs. vehicle). (C,D) Analysis of caspase-3 and -9 activation by static cytometry in Hep3B cells treated for 24 h with
increasing concentrations of EFV, using 2 mM STS treatment as a control. Representative cytograms (C) show caspase-3 and caspase-9 activation
detected as mean fluorescence. The histograms (D) summarize the fluorescence data and represent the % of positive cells in the total cellular
population (shaded area). Data shown as mean  SEM (n = 3–6).
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independent oxidation processes, we performed
additional experiments to ensure the specificity of
the signal detected. Incubation of Hep3B cells with
50 mM FeTCPP, a SOD mimetic (Liu and Schubert,
2009), largely prevented the EFV-induced increase
in MitoSOX fluorescence (data not shown), suggest-
ing that superoxide was responsible for the increase
in the fluorescent signal. Moreover, taking into con-
sideration recent reports that the superoxide-
dependent MitoSOX oxidation product exhibits
higher selectivity with excitation at 390 nm (Robin-
son et al., 2006), we detected its fluorescence in a
multi-well plate fluorometer with excitation/
emission maxima at 390/530 nm and confirmed
that the increased signal induced by EFV in Hep3B
cells after 24 h treatment was concentration-
dependent (Supporting Information Figure S1).
In keeping with the results of superoxide produc-
tion, fluorimetric quantification revealed a signifi-
cant decrease in the intracellular GSH content after
4 h treatment with EFV 25 mM or 50 mM (Figure 4B).
Parallel measurements using the fluorescent dye
TMRM also revealed a significant decrease in the
mitochondrial transmembrane potential (Dym) after
just 1 h treatment with EFV (Figure 4C). A similar
decrease in the Dym was detected at 6 and 24 h (data
not shown). The mitochondrial changes induced by
1 h of EFV incubation proved to be reversible, since
removal of the drug led to rapid recovery (1 h) of
both superoxide production and Dym to levels
similar to those observed in the steady-state (Sup-
porting Information Figure S2).
The mitotoxic effect of EFV was reproduced in
human primary hepatocytes, which exhibited both
a concentration-dependent increase in mitochon-
drial superoxide production and a significant
decrease in Dym following incubation with the drug
(Figure 5). Importantly, these cells were more sensi-
tive to EFV treatment (1 h) than immortal lines, and
the effects observed were detected with lower con-
centrations of the drug. In particular, Dym was sig-
nificantly affected by 10 mM of EFV, a concentration
that failed to influence the same parameter in
Hep3B cells.
EFV treatment induced an increase in
mitochondrial mass
Figure 6 shows that incubation (1, 6 and 24 h) with
EFV 50 mM, but not 10 or 25 mM, induced a time-
dependent increase in the mitochondrial mass mea-
sured using the cardiolipin-specific fluorocrome
NAO. These results were confirmed with another
fluorescent dye, Mitotracker Green FM (results not
shown). To further confirm the mitochondrial mass
increase induced by EFV, we assessed the mitochon-
drial protein content. Figure 7A shows the effect of
EFV on the expression of several mitochondrial pro-
teins evaluated by Western blot using whole-cell
protein extracts where the evaluations were per-
formed after 8 and 24 h of treatment. Although a
similar trend was observed in both incubation
periods, greater changes were recorded after 24 h of
exposure to EFV. The results (Figure 7A) suggest a
concentration-dependent increase in the cellular
content of Porin, CV subunit a, and b, cyt c and AIF.
CIV-subunit II, a mitochondrial DNA-encoded
protein, was only slightly and not significantly
increased by EFV 50 mM. Interestingly, EFV 50 mM
produced a major decrease in the protein expression
of all three Complex I subunits studied, CI 17, 20
and 39 kDa, thus pointing to a possible defect in the
biogenesis of Complex I. Having detected an
increased mitochondrial mass and overall rise in
Figure 4
Effect of Efavirenz (EFV) treatment on mitochondrial redox state. (A)
Superoxide production. MitoSOX fluorescence in Hep3B cells treated
with increasing concentrations of EFV and vehicle for 1, 6 and 24 h
using rotenone 25 mM as a positive control. (B) GSH concentration.
The histogram shows the relative intracellular GSH levels (previously
normalized to the cell number) in Hep3B cells treated with EFV for
4 h. (C) Mitochondrial membrane potential. TMRM fluorescence in
Hep3B cells treated with increasing concentrations of EFV for 1 h,
using 10 mM FCCP as a positive control. Data (mean  SEM, n =
7–11) were calculated as % of control fluorescence value (untreated
cells) and analysed by one-way ANOVA multiple comparison test
followed by Newman–Keuls test (*P < 0.05, **P < 0.01, ***P < 0.001
vs. vehicle). Data for rotenone and FCCP were independently analy-
sed by Student’s t-test, § or #P < 0.001.
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mitochondrial protein content, we next decided to
assess the process of mitochondrial biogenesis
through analysis of the relative mtDNA copy
number. After exposure of Hep3B cells to EFV for 8
and 24 h, the relative copy number of mtDNA nor-
malized to that of nuclear DNA did not present
significant changes when compared with vehicle-
treated cells (Figure 7B).
Treatment with Trolox improves the effect
of EFV
Figure 8 shows the results obtained with static
cytometry experiments performed on Hep3B cells
treated with EFV 50 mM for 24 h in the presence of
0.5 mM Trolox. The cytograms in Figure 8A exhibit
data from a representative experiment in which
Trolox treatment led to a partial recovery of the
cell number and partially reversed the increase
in chromatin condensation (4′,6-diamino-2-
phenylindole channel, left panel) and the increase
in mitochondrial mass (FITC channel, right panel)
induced by EFV treatment. A summary of the
effect of 0.5 mM Trolox on cell survival is provided
in Figure 8B.
Discussion
There is growing concern about the side-effects asso-
ciated with EFV-containing therapies, which include
hepatotoxicity. The association between plasma
concentration and adverse hepatic effects is well
established, and up to 10% of HIV patients treated
with EFV exhibit increases in liver enzymes that
may require discontinuation of the therapy (Abres-
cia et al., 2005; Kappelhoff et al., 2005). Further-
more, the potential for hepatotoxicity is known to
increase considerably in the presence of HBV/HCV
co-infection (Sulkowski et al., 2002; Kontorinis and
Dieterich, 2003; Brück et al., 2008), though the
reason for this remains elusive. The present study
shows that EFV reduces the proliferation and viabil-
ity of hepatic cells in vitro through an acute mito-
toxic effect. These effects were rapid and
concentration-dependent, with 10 mM inducing
some changes and EFV 50 mM proving to be
extremely cytotoxic. Although a static in vitro cell
system is clearly different to the in vivo situation, the
experimental settings that we employed were
chosen to resemble clinical conditions as closely as
Figure 5
Effect of Efavirenz (EFV) treatment (1 h) on primary human hepatocytes. Rotenone 25 mM or FCCP 10 mM were used as positive controls. (A)
Representative images of mitochondrial superoxide production, detected as MitoSOX fluorescence (upper panel: MitoSOX fluorescence in red,
Hoechst-stained nuclei shown in blue), and Dym, detected as TMRM fluorescence (lower panel: TMRM fluorescence in red, Hoechst-stained nuclei
shown in blue). (B) Histograms summarizing MitoSOX fluorescence (left panel) and TMRM fluorescence (right panel). Data (mean  SEM, n =
3–6), calculated as % of control (untreated cells) fluorescence value were analysed by one-way ANOVA multiple comparison test followed by
Newman–Keuls test. *P < 0.05, **P < 0.01, ***P < 0.001 versus vehicle.
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possible. Thus, we used the human hepatoma cell
line Hep3B, which has an active cytochrome P450
system (Zhu et al., 2007), and several experiments
were reproduced using primary human hepatocytes.
Moreover, the range of concentrations employed
was chosen taking into account the important
interindividual variability reported for the
pharmacokinetics of this drug. Although the recom-
mended daily dose of EFV for adults (600 mg)
usually results in plasma levels of 3.17 to 12.67 mM
(Starr et al., 1999; Staszewski et al., 1999), several
clinical studies have shown that as many as 20% of
patients exhibit higher levels, with values of 30–50
mM having been reported (Marzolini et al., 2001;
Taylor et al., 2001; Burger et al., 2006). Additionally,
there are numerous reports of interactions with a
variety of drugs co-administered during the treat-
ment of HIV-1 and which result in a significant
increase in the Cmax of EFV (Summary of Sustiva
Product Characteristics, 2010). In our study, the
inhibitory effects of EFV on proliferation and viabil-
ity were not specific for hepatic cells and were found
to be even more intense in the other two cell lines
evaluated (HeLa and HUVEC). These results indicate
that the therapeutic effects of EFV are manifested
within a narrow range of concentrations and
suggest that the drug may be harmful to other
tissues.
Our results expand the limited and often contra-
dictory information regarding the effects of EFV on
cellular toxicity. For instance, incubation with
12.4 mM EFV for several weeks is reported not to
reduce the proliferation of HepG2 cells (Walker
et al., 2002). The discrepancy between this finding
and our results obtained with Hep3B may be due to
metabolic differences between the two hepatoma
cell lines (Zhu et al., 2007). On the contrary, 7 days
in the presence of 10 or 20 mM EFV results in a
significant decrease in the growth of anaplastic
thyroid carcinoma ARO cells and poorly differenti-
ated thyroid carcinoma FRO cells (Landriscina et al.,
2005). Although these actions have been attributed
to changes in the cell cycle, EFV has also been
shown to induce caspase- and mitochondria-
dependent apoptosis in Jurkat-T and human periph-
eral blood mononuclear cells in different time
frames (Pilon et al., 2002).
There is a direct link between apoptosis and
hepatotoxicity (Labbe et al., 2008; Malhi and Gores,
2008; Walters et al., 2009), and there is a growing list
Figure 6
Effect of Efavirenz (EFV) treatment on mitochondrial mass. (A) 10-N-nonyl-acridine orange chloride (NAO) fluorescence in Hep3B cells treated with
increasing concentrations of EFV for 1, 6 and 24 h. Data (mean  SEM, n = 5–9), calculated as % of control (untreated cells) fluorescence were
analysed by one-way ANOVA multiple comparison test followed by Newman–Keuls test, **P < 0.01 and ***P < 0.001, versus vehicle. (B)
Representative fluorescence microscopy images (20¥) of Hep3B cells treated with 50 mM EFV or vehicle (6 h) and stained with Hoechst, MitoSOX
and NAO.
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Figure 7
Effect of Efavirenz (EFV) treatment on mitochondrial protein expression. Hep3B cells were treated with increasing EFV concentrations for 8 and
24 h. (A) Representative WB image (24 h) and histograms expressing quantification of the expression of various proteins (8 and 24 h) are shown.
Comparisons were made with the protein expression in control (untreated) cells, which was given a relative value of 100% in each individual
experiment. Data (mean  SEM, n = 3–7) were analysed by one-way ANOVA multiple comparison test followed by Newman–Keuls test, *P < 0.05
and **P < 0.01 versus vehicle. (B) Quantitative genomic PCRs used to quantify the relative ratio of mtDNA/nDNA, data represented as mean 
SEM, n = 3–7.
Figure 8
Effect of the antioxidant Trolox on Efavirenz (EFV) 50 mM-treated Hep3B cells. (A) Representative cytograms of untreated control, EFV 50 mM-
treated cells and cells treated with EFV 50 mM + 0.5 mM Trolox, showing mean 4′,6-diamino-2-phenylindole (DAPI) (Hoechst) fluorescence (left
panel) and mean fluorescein isothiocyanate (FITC) (10-N-nonyl-acridine orange chloride) fluorescence (right panel). (B) Histogram of cell number
analysed by static cytometry. Data (mean  SEM, n = 3–5) were analysed by Student’s unpaired t-test, *P < 0.05 versus vehicle.
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of pro-apoptotic compounds associated with liver
disorders (Labbe et al., 2008; Malhi and Gores,
2008). In our study, cells treated with 50 mM of EFV
displayed clear apoptotic features, such as exposure
of phosphatidylserine on the plasma membrane,
chromatin condensation, nuclear fragmentation
and translocation of the mitochondrial apoptotic
proteins cyt c and AIF. In addition, we detected
modifications of the cell cycle characteristic of apo-
ptosis in EFV 50 mM-treated cells, namely an
increase in the subG1 subpopulation and also G2M
arrest. Finally, our evidence points to the involve-
ment of the mitochondrial pathway in the induc-
tion of apoptosis, as indicated by the specific
activation of caspase-3 and -9 but not of caspase-8
(Danial and Korsmeyer, 2004; Li and Yuan, 2008).
Alterations in mitochondrial physiology and
mitochondrial oxidative stress-induced cellular
damage are considered to constitute a central event
in apoptosis (Valko et al., 2006). Here, we provide
evidence of the involvement of mitochondrial dys-
function and oxidative stress in the cellular toxicity
produced by EFV. In particular, we observed a sig-
nificant time- and concentration-dependent
increase in mitochondrial superoxide production,
which was paralleled by a drop in Dym and was
followed by a reduction in the intracellular GSH
content. In addition, treatment with the antioxi-
dant Trolox improved cell survival, a finding that
could be of special clinical relevance. These results
are in line with those of a recent publication by our
group, in which we have reported a direct inhibitory
effect of EFV on mitochondrial respiration in both
Hep3B and primary human hepatocytes (Blas-García
et al., 2010). In that study, measurement of oxygen
consumption in isolated mitochondria subjected to
EFV revealed that this defect occurred specifically at
the level of Complex I of the electron transport
chain. Furthermore, the fact that the mitochondrial
changes observed in the present study occurred fol-
lowing short exposure to the drug (1 h) suggests that
they are unrelated to variations in gene expression
or in the number of these organelles, which appear
after much longer periods and which, until now,
were thought to be the main mechanism of the
mitochondrial toxicity of antiretroviral drugs. This
hypothesis is reinforced by the fact that the modi-
fications in mitochondrial function that we
observed with EFV were reversed soon after removal
of the drug.
Some mitochondrial effects were obtained with
concentrations of EFV that did not trigger cell death
within the time frame of our experiments. It is pos-
sible that the effects of the lower EFV concentrations
employed in our experiments are accumulative, and
would therefore need to be monitored over a longer
period of time in order for the damage to become
visible. However, it is also feasible that these effects
may represent levels of mitochondrial stress below
those necessary to induce apoptosis, but which
become pro-apoptotic in the presence of other
stimuli that further compromise the mitochondria.
This is in accordance with the fact that most cases of
hepatotoxicity related to EFV coincide with
co-morbidities that further interfere with mitochon-
drial function (Sulkowski et al., 2002). The threshold
of EFV-induced mitochondrial stress may also vary
depending on the cell type, and it is thus of particu-
lar clinical relevance that the effects of EFV were
more pronounced in human primary hepatic cells
than in Hep3B. Nevertheless, our results do not
explain the recent clinical case of an EFV-treated
patient who suffered acute liver failure in the appar-
ent absence of mitochondrial damage (Turkova
et al., 2009), an adverse effect that could have been
related to the co-existence of other risk factors for
hepatotoxicity, including idiosyncratic reaction
to EFV or the various drugs co-administered
with EFV.
Finally, we present data indicating that an
increase in mitochondrial mass precedes apoptosis
in 50 mM EFV-treated Hep3B cells. This is suggested
by the augmented cardiolipin content and
enhanced expression of mitochondrial proteins,
which was not paralleled by an increase in the
mtDNA/nuclear DNA copy number ratio. Interest-
ingly, there are several reports of mitochondrial bio-
genesis occurring in the absence of an increase in
the mtDNA copy number (Lee and Wei, 2005).
Moreover, there is mounting evidence of similar
increases in mass and/or proliferation of mitochon-
dria in a number of cell types during apoptotic cell
death (Mancini et al., 1998; Mahyar-Roemer et al.,
2001; Kluza et al., 2004). Although the implication
of this increase remains controversial, it is plausible
that it constitutes an early response to stress by
which the cell adapts to new energy demands and
repairs injuries, thus increasing its chances of sur-
vival (Lee and Wei, 2005). However, in our case, it
was followed by apoptotic cell death, which may be
proof that the increased mitochondrial mass in our
model was not fully functional. This is in accor-
dance with the progressive accumulation of ROS
and the reduction in the protein expression of
Complex I subunits. The latter observation, which is
in line with our recent finding that EFV directly
inhibits Complex I in isolated mitochondria (Blas-
García et al., 2010), points to a possible deleterious
effect of EFV on Complex I biogenesis. The fact that
Trolox partially reversed the effects of EFV on mito-
chondrial mass further implicates the generation of
oxidative stress in this toxic effect of EFV.
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In conclusion, the present study demonstrates
that EFV is mitotoxic and pro-apoptotic in human
hepatic cells in vitro, which may be relevant to the
understanding of the hepatotoxicity associated with
this drug. Moreover, since EFV is usually adminis-
tered in conjunction with two NRTI, which are well-
known to have deleterious effects on mitochondria,
it is tempting to speculate about potential drug
combinations in which these and other serious side-
effects may be enhanced.
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Figure S1 Effect of EFV on mitochondrial superox-
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24 h, detected with a ‘Fluoroscan’ multi-well plate
fluorometer. Data (mean SEM, n = 5), calculated as
% of control (untreated cells) fluorescence value,
were analysed by one-way ANOVA multiple compari-
son test followed by Newman–Keuls test, *P < 0.05,
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were independently analysed by Student’s t-test,
#P < 0.01.
Figure S2 Effect of EFV removal on mitochondrial
function in Hep3B cells. Histograms summarizing
data of mean MitoSOX fluorescence (upper panel)
and mean TMRM fluorescence (lower panel) in cells
treated with increasing concentrations of EFV for
1 h and in cells where EFV was removed after the
treatment and fluorescence was recorded 1 h after
its removal. Data (mean  SEM, n = 3–6), calculated
as % of control (untreated cells) fluorescence value,
were analysed by one-way ANOVA multiple compari-
son test followed by Newman–Keuls test, *P < 0.05,
***P < 0.001 versus vehicle.
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